Introduction：Basic information about CAS 153537-73-6|Plevitrexed, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Plevitrexed |
|---|
| CAS Number | 153537-73-6 | Molecular Weight | 532.52600 |
|---|
| Density | 1.44g/cm3 | Boiling Point | / |
|---|
| Molecular Formula | C26H25FN8O4 | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
| Name | Plevitrexed |
|---|
| Synonym | More Synonyms |
|---|
Plevitrexed BiologicalActivity
| Description | Plevitrexed (ZD 9331; BGC 9331) is an orally active and potent thymidylate synthase (TS) inhibitor with a Ki of 0.44 nM. Plevitrexed is taken up via the α-folate receptor as well as the reduced folate carrier. Plevitrexed is used for gastric cancer in clinical[1][2][3]. |
|---|
| Related Catalog | Signaling Pathways >>Apoptosis >>Thymidylate SynthaseResearch Areas >>Cancer |
|---|
| In Vitro | ZD9331 inhibits the transport of [3H]-methotrexate into L1210 and W1L2 cells with a Ki of∼1 µM[3]. |
|---|
| References | [1]. Tochowicz A, et al. Development and binding mode assessment of N-[4-[2-propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-γ-glutamyl-D-glutamic acid (BGC 945), a novel thymidylate synthase inhibitor that targets tumor cells. J Med Chem. 2013 Jul 11;56(13):5446-55. [2]. A. Thomas, et al. A phase I/II study of plevitrexed with nutritional vitamin supplementation in gastric cancer. [3]. Marsham PR, et al. Design and synthesis of potent non-polyglutamatable quinazoline antifolate thymidylate synthase inhibitors. J Med Chem. 1999 Sep 23;42(19):3809-20. |
|---|
Chemical & Physical Properties
| Density | 1.44g/cm3 |
|---|
| Molecular Formula | C26H25FN8O4 |
|---|
| Molecular Weight | 532.52600 |
|---|
| Exact Mass | 532.19800 |
|---|
| PSA | 169.85000 |
|---|
| LogP | 2.03860 |
|---|
| Index of Refraction | 1.683 |
|---|
Synonyms
| (2S)-2-((4-(((2,7-Dimethyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl)(prop-2-ynyl)amino)-2-fluorobenzoyl)amino)-4-(1H-tetrazol-5-yl)butanoic acid |
| Vamidex |
| BGC 9331 |
| (aS)-a-[[4-[[(1,4-Dihydro-2,7-dimethyl-4-oxo-6-quinazolinyl)methyl]-2-propynylamino]-2-fluorobenzoyl]amino]-1H-tetrazole-5-butanoic Acid |
| ZD 9331 |
| FLUOROBENZAMIDO)-4-(1H-TETRAZOL-5-YL)BUTYRIC ACID |
